Drug Profile
Research programme: monoclonal antibodies - Human Genome Sciences/Xencor
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Human Genome Sciences
- Developer Human Genome Sciences; Xencor
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Immunological-disorders in USA (Parenteral)
- 03 Aug 2012 Human Genome Sciences has been acquired by GlaxoSmithKline
- 08 Feb 2008 Preclinical trials in Immunological disorders in USA (Parenteral)